Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo by Hawiger, Daniel et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/09/769/11 $5.00
Volume 194, Number 6, September 17, 2001 769–779
http://www.jem.org/cgi/content/full/194/6/769
 
769
 
Dendritic Cells Induce Peripheral T Cell Unresponsiveness 
Under Steady State Conditions In Vivo
 
Daniel Hawiger,
 
1 
 
Kayo Inaba,
 
3, 5
 
 Yair Dorsett,
 
1
 
 Ming Guo,
 
1
 
Karsten Mahnke,
 
3
 
 Miguel Rivera,
 
3
 
 Jeffrey V. Ravetch,
 
4
 
Ralph M. Steinman,
 
3
 
 and Michel C. Nussenzweig
 
1, 2
 
1
 
Laboratory of Molecular Immunology, 
 
2
 
Howard Hughes Medical Institute, 
 
3
 
Laboratory of Cellular 
Physiology and Immunology, and 
 
4
 
Laboratory of Molecular Genetics and Immunology, 
The Rockefeller University, New York, NY 10021
 
5
 
Laboratory of Immunobiology, Graduate School of Biostudies, Kyoto University,
Kyoto 606-8502, Japan
 
Abstract
 
Dendritic cells (DCs) have the capacity to initiate immune responses, but it has been postulated
that they may also be involved in inducing peripheral tolerance. To examine the function of
DCs in the steady state we devised an antigen delivery system targeting these specialized anti-
gen presenting cells
 
 
 
in vivo using a monoclonal antibody to a DC-restricted endocytic recep-
tor, DEC-205. Our experiments show that this route of antigen delivery to DCs is several or-
ders of magnitude more efficient than free peptide in complete Freund’s adjuvant (CFA) in
inducing T cell activation and cell division. However, T cells activated by antigen delivered to
DCs are not polarized to produce T helper type 1 cytokine interferon 
 
 
 
 and the activation re-
sponse is not sustained. Within 7 d the number of antigen-specific T cells is severely reduced,
and the residual T cells become unresponsive to systemic challenge with antigen in CFA.
Coinjection of the DC-targeted antigen and anti-CD40 agonistic antibody changes the out-
come from tolerance to prolonged T cell activation and immunity. We conclude that in the
absence of additional stimuli DCs induce transient antigen-specific T cell activation followed
by T cell deletion and unresponsiveness.
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Introduction
 
Dendritic cells (DCs)
 
*
 
 are uniquely potent inducers of pri-
mary immune responses in vitro and in vivo (1, 2). In tissue
culture experiments, DCs are typically two orders of mag-
nitude more effective as APCs than B cells or macrophages
 
(3, 4). In addition, purified antigen-bearing
 
 
 
DCs injected
into mice or humans migrate to lymphoid tissues and effi-
ciently induce specific immune responses (5–7). Likewise,
DCs migrate from peripheral tissues to lymphoid organs
during contact allergy (8, 9) and transplantation (10), two
of the most powerful known stimuli of T cell immunity in
vivo. Based on these and similar experiments, it has been
proposed that the principal function of DCs is to initiate T
cell–mediated immunity (1). However, nearly all of these
experiments involved DC purification or culture in vitro
 
,
 
or some perturbations in vivo that induce major alterations
in DC maturation and function. Thus, the physiologic
function of DCs in the steady state has not been deter-
mined (6, 11).
There is indirect evidence from a number of different
laboratories suggesting that DCs may play a role in main-
taining peripheral tolerance (summarized in reference 12).
For example, injection of mice with 33D1, a rat mono-
clonal antibody to an unknown DC antigen, appeared to
induce T cell unresponsiveness to the rat IgG (13). How-
ever, the specificity of antigen delivery was uncertain and
the relevant T cell responses could not be analyzed di-
rectly. In addition, peripheral tolerance to ovalbumin and
hemagglutinin expressed in pancreatic islets was found to
be induced by bone marrow–derived APCs (14–16), but
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the identity of these antigen presenting cells has not been
determined (17).
 
Materials and Methods
 
Mice.
 
6–8-wk-old females were used in all experiments and
were maintained under specific pathogen free conditions.
B10.BR, B6.SJL (CD45.1), and B6/MRL (Fas lpr) mice were
purchased from The Jackson Laboratory. 3A9 transgenic mice
were maintained by crossing with B10.BR mice. To obtain
CD45.1 3A9 or 3A9/lpr T cells, B6.SJL or B6/MRL mice were
crossed extensively with 3A9 mice and tested for CD45.1 and I-A
 
k
 
,
by flow cytometry. Fas lpr mutation was tested by PCR. Mice
were injected subcutaneously with peptide in CFA and subcuta-
neously or intravenously with chimeric antibodies. All experi-
ments with mice were performed in accordance with National
Institutes of Health guidelines.
 
Flow Cytometry and Antibodies Used for Staining.
 
CD4- (L3T4),
MHC II- (10-3.6), CD11c- (HL3), CD11c- (HL3), B220-
(RA3-6B2), or CD3- (145-2C11), CD80(B7-1)-(16-10A1) I-A
 
k
 
-
(10-3.6) CD45.1- (A20), Il-2- (JES6-5H4), IFN-
 
 
 
- (XMG1.2),
CD40- (HM40-3-FITC), CD86(B7-2)- (GL1) specific antibod-
ies were from BD PharMingen. Rat IgG-PE
 
 
 
(goat
 
 
 
anti–rat IgG)
specific antibody was from Serotec. 3A9 T cell receptor (1G12)–
specific antibody was a gift from Dr. Emil Unanue, Washington
University, St. Louis, MO (18).
For visualization of rat IgGs on surface of mononuclear cells,
lymphoid cells were purified from peripheral LNs 14 h after anti-
body injection and stained with anti–rat IgG-RPE
 
 
 
(goat
 
 
 
anti–rat
IgG-RPE; Serotec) to visualize surface bound NLDC145 and
GL117 antibodies. The cells were then incubated in mouse serum
to block nonspecific binding and stained with FITC anti-CD11c
(HL3), or -B220 (RA3-6B2), or -CD3 (145-2C11).
For intracellular cytokine staining, lymphocytes were stimu-
lated in vitro for 4 h with leukocyte activation cocktail (BD
PharMingen) according to the manufacturer’s manual. Cells
were fixed and permeabilized using cytofix/cytoperm buffer
from BD PharMingen.
 
Immunohistology.
 
Popliteal LNs were removed from antibody
injected mice and 5-
 
 
 
m cryosections (Microm; ZEISS) were
prepared. Tissue specimens were fixed in acetone (5 min, room
temperature [RT]) air dried, and stained in a moist chamber.
The injected antibodies were detected by incubating the sections
with streptavidin Cy3 or streptavidin-FITC (Jackson Immuno-
tech). In double labeling experiments, the PE-conjugated anti-
bodies were added for additional 30 min. Specimens were exam-
ined using a fluorescence microscope and confocal optical
sections of 
 
 
 
0.3-
 
 
 
m thickness were generated using deconvolu-
tion software (Metamorph).
 
Constructing and Production of Hybrid Antibodies.
 
Total RNA
was prepared from NLDC-145 (19) and GLII7 (gift of R.J. Hodes,
National Institutes of Health, Bethesda, MD) hybridomas (both
rat IgG2a) using Trizol (GIBCO BRL). Full-length Ig
cDNAs were produced with 5
 
 
 
-RACE PCR kit (GIBCO BRL)
using primers specific for 3
 
 
 
-ends of rat IgG2a and Ig kappa. The
V regions were cloned in frame with mouse Ig kappa constant re-
gions and IgG1 constant regions carrying mutations that interfere
with FcR binding (20). DNA coding for hen egg lysozyme (HEL)
peptide 46–61 with spacing residues on both sides was added to
the C terminus of the heavy chain using synthetic oligonucle-
otides. Gene specific primers for cloning of rat IgG2a and Ig
kappa: 3
 
 
 
-ATAGTTTAGCGGCCGCGATATCTCACTAA-
CACTCATTCCTGTTGAAGCT; 3
 
 
 
-ATAGTTTAGCGGC-
CGCTCACTAGCTAGCTTTACCAGGAGAGTGGGAGAG-
ACTCTTCT; HEL peptide fragment construction: 5
 
 
 
-CTAGC-
GACATGGCCAAGAAGGAGACAGTCTGGAGGCTCGAG-
GAGTTCGGTAGGTTCACAAACAGGAAC; 5
 
 
 
-ACAGACG-
TAGCACAGACTATGGTATTCTCCAGATTAACAGCAG-
GTATTATGACGGTAGGACATGATAGGC; 3
 
 
 
-GCTGTA-
CCGGTTCTTCCTCTGTCAGACCTCCGAGCTCCTCAA-
GCCATCCAAGTGTTTGTCCTTGTGTCTG; 3
 
 
 
-CCATC-
GTGTCTGATACCATAAGAGGTCTAATTGTCGTCCATA
ATACTGCCATCCTGTACTATCCGCCGG.
Hybrid antibodies were transiently expressed in 293 cells after
transfection using calcium-phosphate. Cells were grown in se-
rum-free DMEM supplemented with Nutridoma SP (Boeh-
ringer). Antibodies were purified on Protein G columns (Amer-
sham Pharmacia Biotech). The concentrations of purified
antibodies were determined by ELISA using goat anti–mouse
IgG1 (Jackson Immunotech).
 
Cell Culture and Proliferation Assays.
 
Pooled axillary, brachial,
inguinal, and popliteal LNs were dissociated in 5% FCS RPMI
and incubated in presence of collagenase (Boehringer) and EDTA
as described (21). For antigen presentation CD19
 
 
 
 and CD11c
 
 
 
cells were purified using microbeads coupled to anti-mouse
CD11c or CD19 IgG (Miltenyi Biotec) and irradiated with 1,500
rad. CD4 T cells were purified by depletion using rat antibodies
supernatants specific for mouse: CD8 (TIB 211), B220 (RA3-
6B2), MHC II (M5/114, TIB 120), F4/80 (F4/80), and magnetic
beads coupled to anti–rat IgG (Dynal). In antigen loading experi-
ments the isolated presenting cells from each experimental group
were cultured in 96-well plates with 2 
 
 
 
 10
 
5
 
 purified 3A9 CD4
 
 
 
T cells. Cultures were maintained for 48 h with [
 
3
 
H]thymidine
(1 
 
 
 
Ci) added for the last 6 h. The results were calculated as a ra-
tio of proliferation in experimental groups to a PBS control
group. The proliferation in PBS controls ranged from 500 to
2,000 cpm.
For T cell proliferation assays in adoptive transfer recipients,
9 
 
 
 
 10
 
4
 
 of the same irradiated CD11c
 
 
 
 cells isolated from spleens
of wild-type B10.BR mice were cultured in 96-well plates with
3 
 
 
 
 10
 
5
 
 T cells from each experimental group. Synthetic HEL pep-
tide, at final concentration of 100 
 
 
 
g/ml, was added to half of the
cultures. Cultures were maintained for 24 h with [
 
3
 
H]thymidine
(1 
 
 
 
Ci/ml) added for the last 6 h. Response to HEL peptide was
determined by subtracting background (no HEL peptide added)
proliferation from proliferation in the presence of HEL peptide.
Proliferation index was calculated as the ratio of the response to
HEL peptide in a given experimental group to the response to
HEL of T cells from a PBS-injected control. Proliferation in PBS
groups ranged from 4,000–8,000 cpm in the presence of peptide
and the response to HEL peptide in these PBS controls was
1,000–3,000 counts above the background. Synthetic HEL 46-61
peptide was provided by the Howard Hughes Medical Institute
Keck Biotechnology Resource Center.
 
Adoptive Transfer.
 
CD4 cells from 3A9 mice were enriched
by depletion as described above, washed 3
 
  
 
with PBS, and 5 
 
 
 
10
 
6
 
 cells injected intravenously per mouse. Alternatively, before
depletion total cells were labeled with 2
 
 
 
 
 
M 5-(6)-carboxyfluo-
rescein diacetate succinimidyl diester (CFSE) in 5% FCS RPMI
(Molecular Probes) at 37
 
 
 
C for 20 min and washed twice.
 
Results
 
To examine the function of DCs in vivo, we devised a
means of delivering antigens to DCs in situ. We used
NLDC145 (19), a monoclonal antibody specific for DEC- 
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205, an endocytic receptor that is a member of a family of
multilectin receptors including the macrophage mannose
receptor (MMR) (22, 23). Like MMR, DEC-205 displays
an NH
 
2
 
-terminal cysteine-rich domain, a fibronectin type
II domain, and multiple C-type lectin domains (22). How-
ever, the tissue distribution of DEC-205 and the MMR
differ in that DEC-205 is highly expressed by DCs within
the T cell areas of lymphoid tissues, particularly on CD8
 
 
 
DCs that have been implicated in cross-priming (24),
whereas the MMR is expressed by some tissue macro-
phages (25, 26). We chose DEC-205 for targeting antigens
to DCs because the cytoplasmic domain of DEC-205 or-
chestrates a distinct endocytic pathway that enhances anti-
gen presentation (23). DEC-205 recycles through late en-
dosomes or lysosomes rich in MHC II, and antigens
delivered to these compartments by DEC-205 are effi-
ciently processed and presented to T cells (23).
To determine whether the NLDC145 antibody targets
DCs in vivo
 
,
 
 we injected mice subcutaneously with puri-
fied NLDC145 or GL117, a nonspecific isotype-matched
rat monoclonal antibody control, and visualized the in-
jected antibody in tissue sections 24 h after injection,
NLDC145 was found localized to scattered large dendritic
profiles in the T cell areas of LNs and spleen while uptake
of control GL117 was undetectable (Fig. 1 A, left and mid-
dle). This pattern was similar to the pattern found when the
antibody was applied to sections directly (Fig. 1 A, right).
The NLDC145-targeted cells were negative for B220 and
CD4, markers for B cells and T cells, respectively, but pos-
itive for characteristic DC markers including MHC II
and CD11c (Fig. 1 B). Thus, subcutaneously injected
NLDC145 targets specifically to CD11c
 
 
 
MHC II
 
 
 
 DCs in
lymphoid tissues in vivo.
To further characterize the lymphoid cells that were tar-
geted by NLDC145 in vivo
 
,
 
 we stained lymphoid cell sus-
pensions from antibody injected mice with anti–rat Ig and
examined the cells by multiparameter flow cytometry (Fig.
1 C). High levels of injected NLDC145 were found on the
surface of most CD11c
 
 
 
 DCs but not on the surface of
B220
 
 
 
 B cells or CD3
 
 
 
 T cells (Fig. 1 C). We conclude
that when NLDC145 is injected into mice it binds effi-
ciently and directly to DCs but not to other lymphoid cells.
To deliver antigens to DCs in vivo
 
,
 
 we produced fusion
proteins with amino acids 46–61 of HEL added to the
COOH terminus of cloned NLDC145 (
 
 
 
DEC/HEL) and
GL117 (GL117/HEL) control antibody (Fig. 1 D). To
minimize antibody binding to Fc (FcR) receptors and fur-
ther ensure the specificity of antigen targeting,
 
 
 
the rat
IgG2a constant regions of the original antibodies were re-
placed with mouse IgG1 constant regions that carry point
mutations interfering with FcR binding (20). The hybrid
antibodies and control Igs without the terminal HEL pep-
tide (
 
 
 
DEC and GL117) were produced by transient trans-
fection in 293 cells (Fig. 1 E).
To determine whether antigens delivered by 
 
 
 
DEC/
HEL were processed by DCs in vivo
 
,
 
 we injected mice
with the hybrid antibodies and controls and tested
CD11c
 
 
 
 DCs, CD19
 
 
 
 B cells and CD11c
 
 
 
CD19
 
 
 
 mono-
 
nuclear cells for their capacity to present HEL peptide to
naive HEL-specific T cells from 3A9 TCR transgenic
mice (27). DCs isolated from antibody-injected mice ex-
pressed levels of CD80 and MHC II similar to those found
on PBS controls and thus showed no signs of increased
maturation, in contrast to what occurs when DCs are stim-
ulated with microbial products like bacterial LPS and CpG
deoxyoligonucleotides (28, 29; Fig. 2 A). Nevertheless
DCs from mice injected with 
 
 
 
DEC/HEL induced strong
T cell proliferative responses, whereas DCs isolated from
PBS-injected mice or mice injected with the control anti-
bodies had no effect (Fig. 2 B). DC isolated 3 d after
 
 
 
DEC/HEL injection showed reduced antigen-presenting
activity (data not shown). In contrast to DCs, B cells and
bulk CD11c
 
 
 
CD19
 
 
 
 mononuclear cells purified from the
same mice showed little antigen-presenting activity (Fig. 2
B). We conclude that antigens can be selectively and effi-
ciently delivered to DC by 
 
 
 
DEC/HEL in vivo
 
,
 
 and the
targeted DCs successfully process and load the peptides
onto MHC II.
As DC isolation leads to activation, we performed
adoptive transfer experiments with HEL-specific trans-
genic T cells to follow the response of these T cells to oth-
erwise unmanipulated, antigen-targeted DCs in vivo.
CD4
 
 
 
 
 
3A9 T cells were transferred into B10.BR recipi-
ents and 24 h later hybrid antibodies were injected subcu-
taneously. To measure T cell responses, CD4
 
 
 
 cells were
isolated from the draining LNs of the injected mice and
cultured in vitro in the presence or absence of added HEL
peptide. T cell responses were measured by [
 
3
 
H]thymidine
incorporation and are shown as proliferation
 
 
 
indices nor-
malized to the PBS control (this index facilitates compari-
son between experiments, see Materials and Methods).
In addition to 
 
 
 
DEC/HEL, GL117/HEL, 
 
 
 
DEC, and
GL117 antibodies, we included 100 
 
 
 
g of HEL peptide in
CFA as a positive control.
As described in previous reports (30, 31), CD4
 
 
 
 T cells
isolated 2 d after challenge with 100 
 
 
 
g of HEL peptide in
CFA showed strong proliferative responses to antigen
when compared with PBS controls (Fig. 3 A). Similar re-
sponses were obtained from mice injected with as little as
0.2 
 
 
 
g of 
 
 
 
DEC/HEL (i.e.,
 
 
 
 
 
4 ng peptide per mouse)
 
 
 
but
not from mice injected with up to 1 
 
 
 
g of 
 
 
 
DEC, GL117,
or GL117/HEL controls (Fig. 3 A, and not shown). We
conclude that antigen delivered to DCs in vivo by 
 
 
 
DEC/
HEL efficiently induces activation of specific T cells.
To determine whether antigen delivered to DCs in vivo
induces persistent T cell activation, we measured T cell re-
sponses to antigen 7 d after the administration of 
 
 
 
DEC/
HEL. CD4 T cells continued to show heightened re-
sponses to antigen
 
 
 
when purified from LNs 7 d after injec-
tion with 100 
 
 
 
g of HEL peptide in CFA (30, 31; Fig. 3
B). In contrast, T cells isolated from mice 7 d after injec-
tion with 
 
 DEC/HEL were no longer activated  when
compared with PBS controls (Fig. 3 B). Thus, T cell acti-
vation by antigen delivered to DCs by  DEC/HEL in vivo
is transient, readily detected at 2 but not 7 d. This transient
activation resembles the CD4 T cell response to large doses772 Dendritic Cells Induce Peripheral T Cell Tolerance in the Steady State
Figure 1. NLDC-145 targets DCs in vivo. (A) Biotinylated NLDC-145 (scNLDC145, left) or rat IgG (scRatIgG, middle) was injected into the hind
footpads (50  g/footpad) and inguinal LNs harvested 24 h later. Sections were stained with Streptavidin Cy3. Control sections from uninjected mice
were stained using biotinylated NLDC145 and streptavidin Cy3 (NLDC145, right). (B) Two-color immunofluorescense. Mice were injected with bio-
tinylated NLDC145 as in panel A. Sections were stained with streptavidin FITC (green) and PE-labeled antibodies (red) to B220 as indicated. Specimens
were analyzed by deconvolution microscopy. Double labeling is indicated by the yellow color. (C) FACS® analysis of lymphoid cells 14 h after injection
with NLDC145 and control GL117 antibody. Histograms show staining with anti–rat IgG on gated populations of CD11c  DCs, B220  B cells, and
CD3  T cells. (D) Diagrammatic representation of hybrid antibodies. (E) Hybrid antibodies. GL117, GL117/HEL,  DEC, and  DEC/HEL antibodies
analyzed by PAGE under reducing conditions, molecular weights in kD are indicated.773 Hawiger et al.
of peptide in the absence of adjuvant, or the response to
self-antigens presented by bone marrow–derived antigen-
presenting cells in the periphery (15, 16, 30–32). To deter-
mine whether the absence of persistent T cell activation in
mice injected with  DEC/HEL is due to clearance of the
injected antigen, multiple doses of  DEC/HEL were ad-
ministered. Repeated injection of  DEC/HEL at 3-d in-
tervals failed to induce prolonged T cell activation (Fig. 3
C). In addition, after 7 or 20 d, T cells initially activated by
 DEC/HEL could not be reactivated when the mice were
challenged with 100  g of HEL peptide in CFA (Fig. 3 D).
In contrast, comparable numbers of 3A9 T cells found in
PBS-injected controls mounted a vigorous response to
challenge with HEL peptide in CFA (compare Figs. 3 D
and 4 C). Thus, the transient nature of the T cell response
in mice injected with  DEC/HEL is not due to a lack of
antigen, and T cells initially activated by DCs under physi-
ologic conditions are unresponsive to subsequent challenge
with antigen even in the presence of strong adjuvants.
Absence of persistent T cell responses could be due to
DC deletion, T cell deletion, or induction of T cell anergy.
To assess DC function in mice receiving multiple doses of
 DEC/HEL, we isolated DCs from these mice and moni-
tored presentation to 3A9 T cells in vitro (Fig. 3 E). DCs
from mice injected with two doses of antibody showed the
same T cell stimulatory activity as DCs isolated from mice
receiving a single injection of  DEC/HEL (Fig. 3 E). In
addition, the transfer of antigen specific T cells into
 DEC/HEL recipients did not alter the ability of the iso-
lated DCs to stimulate 3A9 T cells in vitro. Thus, the tran-
sient nature of the T cell response to DC-targeted antigens
in vivo is not the result of a lack of antigen-bearing DCs.
To examine the fate of 3A9 T cells after exposure to an-
tigen presented by DCs in vivo, we performed adoptive
transfer experiments with CD45.1  3A9 T cells labeled
with CFSE, a reporter dye for cell division. As described
previously, T cells challenged with peptide in CFA divide,
upregulate CD69 but not CD25, and produce IL-2 and
IFN-  but not IL-4 or IL-10. These cells are therefore
considered to be Th1 polarized (30, 31; Fig. 4, A and B,
and not shown). A burst of cell division and increase of
CD69 but not CD25 expression was also seen after injec-
tion with 0.2  g  DEC/HEL but not with GL117/HEL.
Only clonotype positive CD4 cells showed these effects
(Fig. 4, A and C, and not shown). However, 3A9 cells acti-
vated by antigen presented on  DEC/HEL targeted DCs
produced only IL-2 but not IFN- , IL-4, or IL-10 at the
time of the assay and thus were not polarized to Th1 or
Th2 phenotype 3 d after antigen challenge. (Fig. 4 B, and
not shown). Therefore, 3A9 cells proliferate in response to
 DEC/HEL targeted DCs in vivo, but the T cells do not
produce a normal effector cell cytokine profile.
Although there was persistent expansion of 3A9 T cells
in regional LNs and spleen 7 and 20 d after challenge with
HEL peptide in CFA (Fig. 4 C, spleen not shown), few
3A9 T cells survived in the LNs or spleen after exposure to
Figure 2. DCs process and present antigen delivered by hybrid antibodies. (A) MHC II and CD80 expression on DCs is not altered by multiple injec-
tions of  DEC/HEL and 3A9 T cells. B10.BR mice transferred with 3A9 T cells and controls were injected subcutaneously in the footpads with 0.2  g
 DEC/HEL or PBS either at 8 d ( DEC/HEL) or at 1 and 8 d ( DEC/HELX2) after transfer (similar results were obtained by intravenous injection of
chimeric antibodies, data not shown). 24 h after the last  DEC/HEL injection, DCs were purified from peripheral LNs and analyzed by flow cytometry
for expression of CD80 and MHC II. Dotted lines in histograms indicate PBS control. (B)  DEC/HEL delivers HEL peptide to DCs in vivo. B10.BR
mice were injected subcutaneously into footpads with 0.3  g of  DEC/HEL or GL117/HEL or  DEC or PBS as indicated. CD11c , CD19 , and
CD11c CD19  cells were isolated from draining LNs 24 h after antibody injection and assayed for antigen processing and presentation to purified 3A9
T cells in vitro. T cell proliferation was measured by [3H]thymidine incorporation and is expressed as a proliferation index relative to PBS controls. The
results are means of triplicate cultures from one of four similar experiments.774 Dendritic Cells Induce Peripheral T Cell Tolerance in the Steady State
antigen delivered by  DEC/HEL. Surviving cells appeared
to be anergic as they could not be stimulated in vivo by
HEL peptide in CFA (see Fig 3 D). The loss of 3A9 T cells
was Fas independent as it also occurred with 3A9/lpr T
cells (Fig. 4 C, and not shown). Thus, the initial expansion
of T cells in response to antigen presented by DCs in vivo
is not sustained, and most of the initial responding T cells
disappear from lymphoid organs by day 7. These cells are
either deleted or persist in extravascular sites (33). If they
do persist outside lymphoid tissues they must be anergic,
because they cannot be activated by further exposure to an-
tigen, including peptide in CFA (Fig. 3 D).
DCs can be stimulated to increase their antigen present-
ing activity and their immunogenic potential by exposure
to bacterial products or CD40L (34–36), a TNF family
member expressed on activated CD4 T cells, platelets, and
mast cells (37). To determine whether the combination of
costimulators and antigen delivery to DCs produces persis-
tent T cell activation, mice were injected with  DEC/
HEL and the agonistic anti-CD40 antibody FGK 45 (38).
In contrast to  DEC/HEL, the combination of  DEC/
HEL and FGK 45 induced persistent T cell activation (Fig.
5 B). The level of T cell activation seen with  DEC/HEL
and FGK 45 at day 7 was comparable to  DEC/HEL at
day 2 or HEL peptide in CFA at day 2 and 7 (compare
Figs. 3 B and 5 B). To determine whether anti-CD40
treatment altered 3A9 T cell numbers in  DEC/HEL-
treated mice, we performed adoptive transfer experiments
Figure 3. In vivo activation of CD4  T cells by  DEC/HEL. In all experiments, 3A9 T cells were transferred into B10.BR mice, and the recipients
were injected subcutaneously in the footpads with antibodies in PBS or 100  g of HEL peptide in CFA 24 h after T cell transfer as indicated. T cell pro-
liferation was measured by [3H]thymidine incorporation and is expressed as a proliferation index relative to PBS controls. (A) T cells are efficiently acti-
vated by antigen delivered by  DEC/HEL. 48 h after challenge with antigen, CD4 T cells were isolated from peripheral LNs and cultured in vitro with
irradiated B10.BR CD11c  cells in the presence or absence of HEL peptide. (B) CD4  T cells are only transiently activated by antigen ( DEC/HEL
0.2  g) delivered to DCs in vivo. CD4  cells were purified from peripheral LNs 2 or 7 d after challenge with antigen and cultured with irradiated
CD11c  cells in the presence or absence of HEL peptide. (C) Failure to induce persistent T cell activation with multiple injections of  DEC/HEL. 3A9
cells were transferred into B10.BR mice and recipients were injected with  DEC/HEL (0.2  g/mouse) once (on day 9 or 2 before analysis) or multiple
times (days 9, 6, and 2 before analysis). Assay for T cell activation was as above. (D) T cells initially activated by  DEC/HEL show diminished response
to rechallenge with HEL peptide in CFA. Recipients were initially injected with either  DEC/HEL (0.2  g), GL117/HEL(0.2  g), or PBS and rechal-
lenged 7 or 20 d later with 100  g of HEL peptide in CFA or with PBS. CD4  cells were purified from peripheral LNs (or spleens, not shown) 2 d after
the rechallenge and cultured with irradiated CD11c  cells in the presence or absence of HEL peptide. Assay for T cell activation was as above. (E) An-
tigen loading of DCs with  DEC/HEL. B10.BR mice with or without transferred 3A9 T cells, were injected subcutaneously with 0.2  g  DEC/HEL
or PBS either at 8 d ( DEC/HEL) or at 1 and 8 d ( DEC/HELX2) after transfer. Antigen loading was measured 1 d after the last dose of  DEC/HEL
by purifying CD11c  DCs from peripheral LNs and culturing with purified 3A9 T cells. The results are means of triplicate cultures from one of three
similar experiments.775 Hawiger et al.
with CD45.1 allotype-marked T cells and assayed by flow
cytometry. Whereas FGK 45 alone showed no effect on
the number of 3A9 T cells in LNs at day 7, the combina-
tion of FGK 45 and  DEC/HEL induced persistent  8–
10-fold expansion of 3A9 T cells, an increase similar to that
seen with HEL peptide in CFA at day 7 (Figs. 5 A and 4).
We conclude that persistent T cell responses can be in-
duced by antigen delivered to DCs in vivo if an additional
activation signal such as CD40 ligation is provided.
To determine if CD40 ligation induced detectable phe-
notypic changes on DCs in our system, we analyzed DCs
from mice transferred with 3A9 cells and injected with
FGK 45 and  DEC/HEL. Consistent with work by others
we found that those DCs upregulated their surface expres-
sion of CD40 and CD86 (39; Fig. 5 C). This increase was
more pronounced in the presence of antigen-specific T
cells suggesting a positive feedback mechanism between ac-
tivated DCs and T cells (Fig. 5 C).
Discussion
Targeting Antigens to DCs In Situ through DEC-205.
Our results establish that antigens can be selectively deliv-
ered to DCs in vivo via the DEC-205 adsorptive endocy-
tosis receptor. DEC-205, originally identified as an antigen
recognized by the monoclonal antibody NLDC-145, offers
several advantages as a receptor that will mediate antigen
targeting to DCs in situ for purposes of antigen presenta-
tion. DEC-205 is expressed in abundance on DCs in the T
cell area (19, 40) and antibodies bound to DEC-205 are ef-
ficiently internalized and delivered to antigen processing
compartments (22, 23). When compared with the MMR, a
closely related receptor, DEC-205 was at least 30 times
more effective in antigen delivery to processing compart-
ments (23). In vivo, anti–DEC-205 monoclonal antibody
targets to DCs very efficiently, a dose of  1  g of antibody
(20 ng of HEL peptide) leading to presentation by DCs that
Figure 4. CD4  T cells divide in re-
sponse to antigen presented by DCs in
vivo, produce IL-2 but not IFN- , and
are then rapidly deleted. (A) CFSE labeled
CD45.1  3A9 T cells were transferred
into B10.BR and 24 h later, the recipients
were injected subcutaneously in the foot-
pads with  DEC/HEL (0.2  g), GL117/
HEL (0.2  g), HEL peptide in CFA, or
PBS. CD4  T cells were purified by neg-
ative selection from regional LNs 3 d after
challenge with antigen and analyzed by
flow cytometry. The plots show staining
with 1G12 anti-3A9 and CFSE intensity
on gated populations of CD4 CD45.1 
cells. The numbers indicate the percent-
age of CFSE high (undivided) and CFSE
low (divided) CD4  T cells. The results
are from one of two similar experiments.
(B) T cells produce IL-2 but not IFN-  in
response to antigens presented on DCs under physiological conditions. 3A9 cells were transferred into B10.BR mice and 24 h later the recipients were
injected subcutaneously in the footpads with  DEC/HEL (0.2  g), GL117/HEL (0.2  g), HEL peptide in CFA. CD4 . Histograms show staining with
anti–IL-2 and anti–IFN-  on gated populations of 3A9 CD4  cells. The thick lines indicate PBS control. (C) Same as in panel A but analysis performed
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was comparable to 100  g of peptide in CFA (Fig. 3 A). It
thus appears that the use of DEC-205 increases the effi-
ciency of DC presentation by at least 100–1,000-fold rela-
tive to current adjuvants.
DCs Induce T Cell Tolerance in the Periphery. Remark-
ably, when DEC-205 targeting is used to charge DCs with
antigen in the steady state, these MHC II rich cells induce
extensive T cell proliferation but do not induce normal
Th-subset polarization or prolonged T cell expansion and
activation. Instead, the T cells exposed to antigen on DCs
in vivo either disappear or become anergic to antigenic re-
stimulation. An initial burst of T cell proliferation followed
by deletion was reported when ovalbumin or hemaggluti-
nin were expressed as transgenes in the beta cells of the
pancreatic islets (15, 16). These, antigens were presented
not by pancreatic beta cells but by bone marrow–derived
APCs in the draining LNs. Our studies, using direct DC
targeting of antigen, suggest that DCs are likely to be the
tolerogenic APCs for self-antigens in vivo (for a review, see
reference 17). Thus, in the steady state, the primary func-
tion of DCs is to maintain peripheral tolerance (Fig. 3, C
and D). While it has been proposed that immature antigen-
bearing DCs can induce tolerance to transplantation anti-
gens and contact allergens (41, 42), the DEC-205 approach
reveals the capacity of DCs to induce profound antigen-
specific tolerance in vivo and in the steady state.
Our findings with peripheral T cells are concordant
with the proposed function for DCs in the thymus (43,
44) which is to establish tolerance in the medulla by in-
ducing the negative selection of self-reactive T cells. Pe-
ripheral tolerance mechanisms are necessary, because
self-reactive T cells escape thymic selection (45) and some
self-antigens do not gain access to the thymus (46). Fur-
thermore, foreign proteins found in the lumens of the air-
ways and intestine do not normally initiate chronic in-
flammation. Nevertheless, DCs are likely to be continually
Figure 5. CD40 ligation prolongs T cell activation in response to antigens delivered to DCs and induces upregulation of costimulatory molecules on
DCs. (A) CD40 ligation induces persistent expansion of 3A9 cells in response to antigens delivered to DCs. CD45.1  3A9 T cells were transferred into
B10.BR mice and 24 h later the recipients were injected subcutaneously in the footpads with 0.2  g of  DEC/HEL alone or 90  g of FGK45 or both
or PBS. CD4  T cells were purified by negative selection from regional LNs 7 d after challenge with antigen and analyzed by flow cytometry using an-
tibodies specific for CD45.1 and CD4. The numbers indicate the percentages of CD4 CD45.1  cells in LNs. (B) CD40 ligation prolongs T cell activa-
tion. 3A9 T cells were transferred into B10.BR mice and 24 h later, recipients were injected subcutaneously in the footpads with 0.2  g of  DEC/HEL
alone or 90  g of FGK45 or both or PBS. After 2 or 7 d, CD4 T cells were isolated from the draining LNs and cultured in vitro with irradiated B10.BR
CD11c  cells in presence or absence of HEL peptide. T cell proliferation was measured by [3H]thymidine incorporation. The results represent triplicate
cultures from two independent experiments. (C) CD40 ligation induces costimulatory molecules on DCs. B10.BR mice with or without 3A9 cell trans-
fer were injected with 90  g FGK45 plus 0.2  g  DEC/HEL or  DEC/HEL or PBS. 3 d later DCs were isolated as in Fig. 2 and analyzed by flow cy-
tometry using antibodies specific for CD11c, B220, CD86, and CD40. Histograms show staining with anti-CD40 and anti-CD86 on gated populations
of DCs. Thick lines indicate control with PBS, which was same as  DEC/HEL alone.777 Hawiger et al.
internalizing potential self-antigens from tissues (47) and
from noninfectious environmental proteins (48). We pro-
pose that in the steady state this uptake of proteins by DCs
leads to peripheral tolerance.
Superficially, the idea that DCs induce tolerance appears
to conflict with abundant evidence that DCs initiate im-
mune responses (1). However, all prior work demonstrat-
ing the function of DCs as inducers of primary immune
responses involved adoptive immunization with DCs cul-
tured in vitro with antigen and then injected (6, 11), or
strong T cell responses in the setting of contact allergy and
transplantation (8–10). Tissue disruption and inflammation
alter DCs, increasing expression of critical costimulators
like B7 (49, 50) MHC-peptide complexes (35) and chemo-
kine receptors (51–53). These altered DCs are referred to as
mature (34, 53–55). The critical role of DC maturation in
immunogenicity (1) is consistent with the idea that the im-
mune system must focus on antigens delivered in the con-
text of danger signals, some of which are registered by pat-
tern recognition receptor (46, 56, 57). Indeed, combined
administration of DC-targeted antigen with an agonistic
anti-CD40 antibody that upregulates costimulatory mole-
cules like CD86 on the surface of DCs (Fig. 5 C), prevents
induction of peripheral tolerance and leads to prolonged T
cell activation.
Our experiments are consistent with the notion that
self-antigens such as serum components and apoptotic cells
captured and presented to T cells by DCs under physio-
logical conditions induce tolerance. In contrast, antigens
taken up by DCs in the context of activation stimuli such
as those found during inflammation or tissue destruction
induce prolonged T cell activation. These two functions
of DCs, maintaining tolerance to self and inducing immu-
nity, are not in conflict because they are elicited under dis-
tinct circumstances, the steady state versus inflammation
and infection. Moreover, the steady state tolerizing func-
tion of DCs may be essential for their subsequent role in
eliciting immunity. During inflammation or infection,
DCs present self-antigens simultaneously with non-self. By
establishing tolerance to self and nonpathogenic environ-
mental proteins before challenge with pathogens, DCs can
focus the adaptive immune system entirely on the patho-
gen, thereby avoiding autoimmunity. The ability to target
antigens to DCs and control their function in vivo has sig-
nificant implications for development of vaccines and
therapies for autoimmunity.
The authors thank Dr. Hitoshi Nagaoka for help with surgical pro-
cedures, Dr. Mark Davis for 3A9 mice, Dr. Fritz Melchers for FGK
45 hybridoma, Dr. Emil Unanue for 1G12 hybridoma, and Dr.
Richard J. Hodes for the GL117 hybridoma. The authors also
thank Dr. Eva Besmer for critical review of the manuscript.
This work was supported in part by Human Frontier Science
(HFS) and grants to M.C. Nussenzweig and R.M. Steinman from
the National Institute of Allergy and Infectious Diseases to R.M.
Steinman and National Institutes of Health to M.C. Nussenzweig
and AI13013, DK program project grant to M.C. Nussenzweig,
R.M. Steinman, and J.V. Ravetch. M.C. Nussenzweig is a Howard
Hughes Medical Institute investigator.
Submitted: 26 June 2001
Revised: 2 August 2001
Accepted: 10 August 2001
References
1. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells
and the control of immunity. Nature. 392:245–252.
2. Thery, C., and S. Amigorena. 2001. The cell biology of anti-
gen presentation in dendritic cells. Curr. Opin. Immunol. 13:
45–51.
3. Inaba, K., R.M. Steinman, W.C. Van Voorhis, and S. Mura-
matsu. 1983. Dendritic cells are critical accessory cells for
thymus-dependent antibody responses in mouse and in man.
Proc. Natl. Acad. Sci. USA. 80:6041–6045.
4. Steinman, R.M., B. Gutchinov, M.D. Witmer, and M.C.
Nussenzweig. 1983. Dendritic cells are the principal stimula-
tors of the primary mixed leukocyte reaction in mice. J. Exp.
Med. 157:613–627.
5. Dhodapkar, M.V., R.M. Steinman, M. Sapp, H. Desai, C.
Fossella, J. Krasovsky, S.M. Donahoe, P.R. Dunbar, V.
Cerundolo, D.F. Nixon, and N. Bhardwaj. 1999. Rapid gen-
eration of broad T-cell immunity in humans after a single in-
jection of mature dendritic cells. J. Clin. Invest. 104:173–180.
6. Inaba, K., J.P. Metlay, M.T. Crowley, and R.M. Steinman.
1990. Dendritic cells pulsed with protein antigens in vitro can
prime antigen-specific, MHC-restricted T cells in situ. J.
Exp. Med. 172:631–640.
7. Lechler, R.I., and J.R. Batchelor. 1982. Restoration of im-
munogenicity to passenger cell-depleted kidney allografts by
the addition of donor strain dendritic cells. J. Exp. Med. 155:
31–41.
8. Macatonia, S.E., S.C. Knight, A.J. Edwards, S. Griffiths, and
P. Fryer. 1987. Localization of antigen on lymph node den-
dritic cells after exposure to the contact sensitizer fluorescein
isothiocyanate. Functional and morphological studies. J. Exp.
Med. 166:1654–1667.
9. Moodycliffe, A.M., V. Shreedhar, S.E. Ullrich, J. Walter-
scheid, C. Bucana, M.L. Kripke, and L. Flores-Romo. 2000.
CD40–CD40 ligand interactions in vivo regulate migration
of antigen-bearing dendritic cells from the skin to draining
lymph nodes. J. Exp. Med. 191:2011–2020.
10. Larsen, C.P., P.J. Morris, and J.M. Austyn. 1990. Migration
of dendritic leukocytes from cardiac allografts into host
spleens. A novel pathway for initiation of rejection. J. Exp.
Med. 171:307–314.
11. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P.
Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D.
Schreiner, P. von den Driesch, et al. 1999. Vaccination with
mage-3A1 peptide-pulsed mature, monocyte-derived den-
dritic cells expands specific cytotoxic T cells and induces re-
gression of some metastases in advanced stage IV melanoma.
J. Exp. Med. 190:1669–1678.
12. Steinman, R.M., S. Turley, I. Mellman, and K. Inaba. 2000.
The induction of tolerance by dendritic cells that have cap-
tured apoptotic cells. J. Exp. Med. 191:411–416.
13. Finkelman, F.D., A. Lees, R. Birnbaum, W.C. Gause, and
S.C. Morris. 1996. Dendritic cells can present antigen in vivo
in a tolerogenic or immunogenic fashion. J. Immunol. 157:
1406–1414.
14. Adler, A.J., D.W. Marsh, G.S. Yochum, J.L. Guzzo, A. Ni-
gam, W.G. Nelson, and D.M. Pardoll. 1998. CD4  T cell
tolerance to parenchymal self-antigens requires presentation778 Dendritic Cells Induce Peripheral T Cell Tolerance in the Steady State
by bone marrow–derived antigen-presenting cells. J. Exp.
Med. 187:1555–1564.
15. Kurts, C., H. Kosaka, F.R. Carbone, J.F. Miller, and W.R.
Heath. 1997. Class I–restricted cross-presentation of exoge-
nous self-antigens leads to deletion of autoreactive CD8  T
cells. J. Exp. Med. 186:239–245.
16. Morgan, D.J., H.T. Kreuwel, and L.A. Sherman. 1999. Anti-
gen concentration and precursor frequency determine the
rate of CD8  T cell tolerance to peripherally expressed anti-
gens. J. Immunol. 163:723–727.
17. Heath, W.R., and F.R. Carbone. 2001. Cross-presentation,
dendritic cells, tolerance and immunity. Annu. Rev. Immunol.
19:47–64.
18. Peterson, D.A., R.J. DiPaolo, O. Kanagawa, and E.R.
Unanue. 1999. Quantitative analysis of the T cell repertoire
that escapes negative selection. Immunity. 11:453–462.
19. Kraal, G., M. Breel, M. Janse, and G. Bruin. 1986. Langer-
hans’ cells, veiled cells, and interdigitating cells in the mouse
recognized by a monoclonal antibody. J. Exp. Med. 163:981–
997.
20. Clynes, R.A., T.L. Towers, L.G. Presta, and J.V. Ravetch.
2000. Inhibitory Fc receptors modulate in vivo cytotoxicity
against tumor targets. Nat. Med. 6:443–446.
21. Inaba, K., M. Pack, M. Inaba, H. Sakuta, F. Isdell, and R.M.
Steinman. 1997. High levels of a major histocompatibility
complex II–self peptide complex on dendritic cells from the
T cell areas of lymph nodes. J. Exp. Med. 186:665–672.
22. Jiang, W., W.J. Swiggard, C. Heufler, M. Peng, A. Mirza,
R.M. Steinman, and M.C. Nussenzweig. 1995. The receptor
DEC-205 expressed by dendritic cells and thymic epithelial
cells is involved in antigen processing. Nature. 375:151–155.
23. Mahnke, K., M. Guo, S. Lee, H. Sepulveda, S.L. Swain, M.
Nussenzweig, and R.M. Steinman. 2000. The dendritic cell
receptor for endocytosis, DEC-205, can recycle and enhance
antigen presentation via major histocompatibility complex
class II–positive lysosomal compartments. J. Cell Biol. 151:
673–684.
24. den Haan, J.M., S.M. Lehar, and M.J. Bevan. 2000. CD8 
but not CD8  dendritic cells cross-prime cytotoxic T cells in
vivo. J. Exp. Med. 192:1685–1696.
25. Guo, M., S. Gong, S. Maric, Z. Misulovin, M. Pack, K.
Mahnke, M.C. Nussenzweig, and R.M. Steinman. 2000. A
monoclonal antibody to the DEC-205 endocytosis receptor
on human dendritic cells. Hum. Immunol. 61:729–738.
26. Linehan, S.A., L. Martinez-Pomares, P.D. Stahl, and S. Gor-
don. 1999. Mannose receptor and its putative ligands in nor-
mal murine lymphoid and nonlymphoid organs: in situ ex-
pression of mannose receptor by selected macrophages,
endothelial cells, perivascular microglia, and mesangial cells,
but not dendritic cells. J. Exp. Med. 189:1961–1972.
27. Ho, W.Y., M.P. Cooke, C.C. Goodnow, and M.M. Davis.
1994. Resting and anergic B cells are defective in CD28-
dependent costimulation of naive CD4  T cells. J. Exp. Med.
179:1539–1549.
28. De Smedt, T., B. Pajak, E. Muraille, L. Lespagnard, E. Hei-
nen, P. De Baetselier, J. Urbain, O. Leo, and M. Moser.
1996. Regulation of dendritic cell numbers and maturation
by lipopolysaccharide in vivo. J. Exp. Med. 184:1413–1424.
29. Sparwasser, T., R.M. Vabulas, B. Villmow, G.B. Lipford,
and H. Wagner. 2000. Bacterial CpG-DNA activates den-
dritic cells in vivo: T helper cell-independent cytotoxic T cell
responses to soluble proteins. Eur. J. Immunol. 30:3591–3597.
30. Kearney, E.R., K.A. Pape, D.Y. Loh, and M.K. Jenkins.
1994. Visualization of peptide-specific T cell immunity and
peripheral tolerance induction in vivo. Immunity. 1:327–339.
31. Van Parijs, L., D.A. Peterson, and A.K. Abbas. 1998. The
Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to
model self and foreign antigens. Immunity. 8:265–274.
32. Aichele, P., K. Brduscha-Riem, R.M. Zinkernagel, H. Hen-
gartner, and H. Pircher. 1995. T cell priming versus T cell
tolerance induced by synthetic peptides. J. Exp. Med. 182:
261–266.
33. Reinhardt, R.L., A. Khoruts, R. Merica, T. Zell, and M.K.
Jenkins. 2001. Visualizing the generation of memory CD4 T
cells in the whole body. Nature. 410:101–105.
34. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van
Kooten, I. Durand, and J. Banchereau. 1994. Activation of
human dendritic cells through CD40 cross-linking. J. Exp.
Med. 180:1263–1272.
35. Inaba, K., S. Turley, T. Iyoda, F. Yamaide, S. Shimoyama,
C. Reis e Sousa, R.N. Germain, I. Mellman, and R.M.
Steinman. 2000. The formation of immunogenic major his-
tocompatibility complex class II–peptide ligands in lysosomal
compartments of dendritic cells is regulated by inflammatory
stimuli. J. Exp. Med. 191:927–936.
36. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation
of soluble antigen by cultured human dendritic cells is main-
tained by granulocyte/macrophage colony–stimulating factor
plus interleukin 4 and downregulated by tumor necrosis fac-
tor alpha. J. Exp. Med. 179:1109–1118.
37. Foy, T.M., A. Aruffo, J. Bajorath, J.E. Buhlmann, and R.J.
Noelle. 1996. Immune regulation by CD40 and its ligand
GP39. Annu. Rev. Immunol. 14:591–617.
38. Rolink, A., F. Melchers, and J. Andersson. 1996. The SCID
but not the RAG-2 gene product is required for S mu-S ep-
silon heavy chain class switching. Immunity. 5:319–330.
39. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E.
Kampgen, N. Romani, and G. Schuler. 1996. High level IL-
12 production by murine dendritic cells: upregulation via
MHC class II and CD40 molecules and downregulation by
IL-4 and IL-10. [published erratum at 184:1590]. J. Exp.
Med. 184:741–746.
40. Witmer-Pack, M.D., W.J. Swiggard, A. Mirza, K. Inaba, and
R.M. Steinman. 1995. Tissue distribution of the DEC-205
protein that is detected by the monoclonal antibody NLDC-
145. II. Expression in situ in lymphoid and nonlymphoid tis-
sues. Cell. Immunol. 163:157–162.
41. Fu, F., Y. Li, S. Qian, L. Lu, F. Chambers, T.E. Starzl, J.J.
Fung, and A.W. Thomson. 1996. Costimulatory molecule-
deficient dendritic cell progenitors (MHC class II ,
CD80dim, CD86 ) prolong cardiac allograft survival in
nonimmunosuppressed recipients. Transplantation. 62:659–
665.
42. Steinbrink, K., M. Wolfl, H. Jonuleit, J. Knop, and A.H.
Enk. 1997. Induction of tolerance by IL-10-treated dendritic
cells. J. Immunol. 159:4772–4780.
43. Matzinger, P., and S. Guerder. 1989. Does T-cell tolerance
require a dedicated antigen-presenting cell? Nature. 338:74–
76.
44. Zal, T., A. Volkmann, and B. Stockinger. 1994. Mechanisms
of tolerance induction in major histocompatibility complex
class II-restricted T cells specific for a blood-borne self-anti-
gen. J. Exp. Med. 180:2089–2099.
45. Bouneaud, C., P. Kourilsky, and P. Bousso. 2000. Impact of
negative selection on the T cell repertoire reactive to a self-
peptide: a large fraction of T cell clones escapes clonal dele-779 Hawiger et al.
tion. Immunity. 13:829–840.
46. Matzinger, P. 1994. Tolerance, danger, and the extended
family. Annu. Rev. Immunol. 12:991–1045.
47. Huang, F.P., N. Platt, M. Wykes, J.R. Major, T.J. Powell,
C.D. Jenkins, and G.G. MacPherson. 2000. A discrete sub-
population of dendritic cells transports apoptotic intestinal
epithelial cells to T cell areas of mesenteric lymph nodes. J.
Exp. Med. 191:435–444.
48. Vermaelen, K.Y., I. Carro-Muino, B.N. Lambrecht, and
R.A. Pauwels. 2001. Specific migratory dendritic cells rapidly
transport antigen from the airways to the thoracic lymph
nodes. J. Exp. Med. 193:51–60.
49. Caux, C., B. Vanbervliet, C. Massacrier, M. Azuma, K.
Okumura, L.L. Lanier, and J. Banchereau. 1994. B70/B7-2 is
identical to CD86 and is the major functional ligand for
CD28 expressed on human dendritic cells. J. Exp. Med. 180:
1841–1847.
50. Inaba, K., M. Witmer-Pack, M. Inaba, K.S. Hathcock, H.
Sakuta, M. Azuma, H. Yagita, K. Okumura, P.S. Linsley, S.
Ikehara, et al. 1994. The tissue distribution of the B7-2 co-
stimulator in mice: abundant expression on dendritic cells in
situ and during maturation in vitro. J. Exp. Med. 180:1849–
1860.
51. Ngo, V.N., H.L. Tang, and J.G. Cyster. 1998. Epstein-Barr
virus-induced molecule 1 ligand chemokine is expressed by
dendritic cells in lymphoid tissues and strongly attracts naive
T cells and activated B cells. J. Exp. Med. 188:181–191.
52. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, R. Of-
fringa, and C.J. Melief. 1998. T-cell help for cytotoxic T
lymphocytes is mediated by CD40-CD40L interactions. Na-
ture. 393:480–483.
53. Sallusto, F., P. Schaerli, P. Loetscher, C. Schaniel, D. Lenig,
C.R. Mackay, S. Qin, and A. Lanzavecchia. 1998. Rapid and
coordinated switch in chemokine receptor expression during
dendritic cell maturation. Eur. J. Immunol. 28:2760–2769.
54. Pierre, P., S.J. Turley, E. Gatti, M. Hull, J. Meltzer, A.
Mirza, K. Inaba, R.M. Steinman, and I. Mellman. 1997. De-
velopmental regulation of MHC class II transport in mouse
dendritic cells. Nature. 388:787–792.
55. Schuler, G., and R.M. Steinman. 1985. Murine epidermal
Langerhans cells mature into potent immunostimulatory den-
dritic cells in vitro. J. Exp. Med. 161:526–546.
56. Janeway, C. 1989. Immunogenicity signals 1,2,3 ... and 0. Im-
munol. Today. 10:283–286.
57. Medzhitov, R., and C. Janeway, Jr. 2000. Innate immune
recognition: mechanisms and pathways. Immunol. Rev. 173:
89–97.